Close

ACOR Financial Facts

Cost of sales: 27.64M
Net loss per share-basic (earnings per share): -0.28
See Full Income Statement

Accumulated other comprehensive income: -3.62M
Total assets: 1.32B
See Full Balance Sheet

Acorda Therapeutics, Inc. (ACOR) Earnings

  |   Expand Research on ACOR
Next EPS Date N/A EPS Growth Rate -139.7% *Last Qtr.
Average EPS % Beat Rate -188.2% Revenue Growth Rate +63.1% *Last Qtr.
Average % Move 1-Wk after EPS -8.4% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/8/23 Q223 -$7.55N/A N/A $29.68MN/A N/A Details
8/4/22 Q222 -$3.15-$0.36 -$2.79$18.2M$29.1M N/A Details
3/4/21 Q420 -$2.50-$1.48 -$1.02$38.16M$34M N/A Details
5/6/21 Q121 -$2.46-$2.54 +$0.08$28.86M$22.15M N/A Details
8/5/21 Q221 -$1.87-$2.09 +$0.22$31.78M$29.94M N/A Details
11/9/21 Q321 -$1.43-$1.56 +$0.13$31.45M$30.57M N/A Details
5/11/23 Q123 -$0.69N/A N/A $22.25MN/A N/A Details
3/9/22 Q421 -$0.67N/A N/A $36.97M$31.01M N/A Details